| Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We have developed a platform technology to generate recombinant vaccines against various infectious diseases by using non-propagative human parainfluenza virus type 2 vector designated as BC-PIV. First we created a vaccine against Ebola virus GP protein, and named as BC-PIV/EBOV-GP. Immunoelectron microscopy revealed that GP protein is abundantly present on the viral surface (collaboration with Prof. Akira Mizoguchi at Mie University). Immunization of mice with the BC-PIV/EBOV-GP resulted in generation of effective neutralizing antibodies against EBOV-GP-pseudotyped vesicular stomatitis virus (collaboration with Prof. Ayato Takada at Hokkaido University). This technology will become a powerful tool to fulfill unmet medical needs, especially against emerging infectious diseases.
|
